Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Selectivity of compounds isolated from the leaves of Nerium indicum Mill. on various human cancer cell lines.

Mae SH, Sofia M, Bolhuis RL, Nooter K, Oostrum RG, Subagus W, Ibnu GG.

Med J Malaysia. 2008 Jul;63 Suppl A:24-5.

PMID:
19024965
2.

T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.

Schaft N, Lankiewicz B, Drexhage J, Berrevoets C, Moss DJ, Levitsky V, Bonneville M, Lee SP, McMichael AJ, Gratama JW, Bolhuis RL, Willemsen R, Debets R.

Int Immunol. 2006 Apr;18(4):591-601. Epub 2006 Feb 28.

PMID:
16507598
3.
4.

Flexible and sensitive method to functionally validate tumor-specific receptors via activation of NFAT.

Schaft N, Lankiewicz B, Gratama JW, Bolhuis RL, Debets R.

J Immunol Methods. 2003 Sep;280(1-2):13-24.

PMID:
12972184
5.

Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.

Schaft N, Willemsen RA, de Vries J, Lankiewicz B, Essers BW, Gratama JW, Figdor CG, Bolhuis RL, Debets R, Adema GJ.

J Immunol. 2003 Feb 15;170(4):2186-94.

6.
7.

Genetic engineering of T cell specificity for immunotherapy of cancer.

Willemsen RA, Debets R, Chames P, Bolhuis RL.

Hum Immunol. 2003 Jan;64(1):56-68. Review.

PMID:
12507815
8.

TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.

Chames P, Willemsen RA, Rojas G, Dieckmann D, Rem L, Schuler G, Bolhuis RL, Hoogenboom HR.

J Immunol. 2002 Jul 15;169(2):1110-8.

9.

Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.

Lamers CH, Willemsen RA, Luider BA, Debets R, Bolhuis RL.

Cancer Gene Ther. 2002 Jul;9(7):613-23.

10.

Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies.

van den Bent MJ, Lamers CH, van 't Veer MB, Sillevis Smitt PA, Bolhuis RL, Gratama JW.

Ann Hematol. 2002 Apr;81(4):187-91. Epub 2002 Mar 26.

PMID:
11976819
11.

A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes.

Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P.

Gene Ther. 2001 Nov;8(21):1601-8.

12.

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.

Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RL, Melief CJ, Huber C, Stauss HJ, Theobald M.

Nat Immunol. 2001 Oct;2(10):962-70.

PMID:
11577350
13.
14.

Interleukin 12 induces activation of fibrinolysis and coagulation in humans.

Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, Bolhuis RL, Stoter G, Huber C, Hack C.

Br J Haematol. 2001 Feb;112(2):499-505.

PMID:
11167854
15.

Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.

Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RL.

Gene Ther. 2000 Aug;7(16):1369-77.

16.

An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells.

Hombach A, Schneider C, Sent D, Koch D, Willemsen RA, Diehl V, Kruis W, Bolhuis RL, Pohl C, Abken H.

Int J Cancer. 2000 Oct 1;88(1):115-20.

18.

Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE.

Clin Cancer Res. 1999 Dec;5(12):3983-9.

19.
20.

Quality control of flow cytometric immunophenotyping of haematological malignancies.

Gratama JW, Bolhuis RL, Van 't Veer MB.

Clin Lab Haematol. 1999 Jun;21(3):155-60. Review.

PMID:
10448596
21.

Large-scale production of natural cytokines during activation and expansion of human T lymphocytes in hollow fiber bioreactor cultures.

Lamers CH, Gratama JW, Luider-Vrieling B, Bolhuis RL, Bast EJ.

J Immunother. 1999 Jul;22(4):299-307.

PMID:
10404431
22.
23.

Preparation for a phase I/II study using autologous gene modified T lymphocytes for treatment of metastatic renal cancer patients.

Bolhuis RL, Willemsen RA, Lamers CH, Stam K, Gratama JW, Weijtens ME.

Adv Exp Med Biol. 1998;451:547-55. No abstract available.

PMID:
10026926
24.

Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.

Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI, Canevari S.

Int J Cancer. 1999 Feb 19;84(1):62-8.

26.

Genetic re-targeting of T lymphocyte specificity.

Bolhuis RL, Gratama JW.

Gene Ther. 1998 Sep;5(9):1153-5. No abstract available.

27.

Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.

Weijtens ME, Willemsen RA, van Krimpen BA, Bolhuis RL.

Int J Cancer. 1998 Jul 17;77(2):181-7.

28.

A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.

de Wit R, Kruit WH, Lamers CH, van 't Veer MB, Luyten AA, van Beurden V, Harteveld M, Planting AS, Schmitz PI, Stoter G, Bolhuis RL, Verweij J.

Br J Cancer. 1998 Jun;77(12):2363-6.

29.

Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.

Luiten RM, Warnaar SO, Sanborn D, Lamers CH, Bolhuis RL, Litvinov SV, Zurawski VR Jr, Coney LR.

J Immunother. 1997 Nov;20(6):496-504.

PMID:
9409456
30.

Analysis of factors contributing to the formation of mononuclear cell aggregates ("escapees") in flow cytometric immunophenotyping.

Gratama JW, van der Linden R, van der Holt B, Bolhuis RL, van de Winkel JG.

Cytometry. 1997 Nov 1;29(3):250-60.

PMID:
9389442
32.

Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients.

Goey SH, Verweij J, Bolhuis RL, de Gooyer D, Eggermont AM, Schmitz PI, Stoter G.

Cancer Immunol Immunother. 1997 Jul;44(5):301-4.

PMID:
9247565
33.

High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.

Kruit WH, Goey SH, Lamers CH, Gratama JW, Visser B, Schmitz PI, Eggermont AM, Bolhuis RL, Stoter G.

J Immunother. 1997 Jul;20(4):312-20.

PMID:
9220321
34.

Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: identification of four variants among wild-type EBV isolates.

Sandvej K, Gratama JW, Munch M, Zhou XG, Bolhuis RL, Andresen BS, Gregersen N, Hamilton-Dutoit S.

Blood. 1997 Jul 1;90(1):323-30.

35.

Reduction of interlaboratory variability in flow cytometric immunophenotyping by standardization of instrument set-up and calibration, and standard list mode data analysis.

Gratama JW, Kraan J, Adriaansen H, Hooibrink B, Levering W, Reinders P, Van den Beemd MW, Van der Holt B, Bolhuis RL.

Cytometry. 1997 Feb 15;30(1):10-22.

PMID:
9056737
36.

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

Kruit WH, Punt CJ, Goey SH, de Mulder PH, Gratama JW, Eggermont AM, Bolhuis RL, Stoter G.

Br J Cancer. 1996 Sep;74(6):951-5.

37.

Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity.

Weijtens ME, Willemsen RA, Valerio D, Stam K, Bolhuis RL.

J Immunol. 1996 Jul 15;157(2):836-43.

PMID:
8752936
38.

Prolonged continuous hepatic artery infusion with interleukin-2 in unresectable liver metastases of colorectal cancer: a phase IA-B study.

Goey SH, Eggermont AM, Oskam R, Wiggers T, Bolhuis RL, Stoter G.

Ann Oncol. 1996 Mar;7(3):317-9. No abstract available.

PMID:
8740799
39.
40.

Targeting of peripheral blood T lymphocytes.

Bolhuis RL, Hoogenboom HR, Gratama JW.

Springer Semin Immunopathol. 1996;18(2):211-26. Review. No abstract available.

PMID:
8908701
41.

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW, Oosterom R, Oskam R, Bolhuis RL, Stoter G.

Br J Cancer. 1995 Nov;72(5):1283-8.

42.

Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions.

Canevari S, Mezzanzanica D, Mazzoni A, Negri DR, Ramakrishna V, Bolhuis RL, Colnaghi MI, Bolis G.

J Hematother. 1995 Oct;4(5):423-7.

PMID:
8581379
44.

Detection of multiple 'Ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx.

Gratama JW, Oosterveer MA, Weimar W, Sintnicolaas K, Sizoo W, Bolhuis RL, Ernberg I.

J Gen Virol. 1994 Jan;75 ( Pt 1):85-94.

PMID:
8113743
45.

Characterization of Epstein-Barr viral strains in parotid gland saliva and peripheral blood of patients with primary Sjögren's syndrome and healthy EBV carriers.

Oosterveer MA, Markusse HM, Lennette ET, Zou JZ, Bolhuis RL, Gratama JW.

J Med Virol. 1993 Dec;41(4):261-9.

PMID:
8106859
46.

Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3.

Blank-Voorthuis CJ, Braakman E, Ronteltap CP, Tilly BC, Sturm E, Warnaar SO, Bolhuis RL.

J Immunol. 1993 Sep 15;151(6):2904-14.

PMID:
8376761
47.

Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3.

van Ravenswaay Claasen HH, van de Griend RJ, Mezzanzanica D, Bolhuis RL, Warnaar SO, Fleuren GJ.

Int J Cancer. 1993 Aug 19;55(1):128-36.

PMID:
8344744
48.

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.

Kruit WH, Bolhuis RL, Goey SH, Jansen RL, Eggermont AM, Batchelor D, Schmitz PI, Stoter G.

J Clin Oncol. 1993 May;11(5):921-4.

PMID:
8487055
49.

Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Gratama JW, Bruin RJ, Lamers CH, Oosterom R, Braakman E, Stoter G, Bolhuis RL.

Clin Exp Immunol. 1993 May;92(2):185-93.

50.

Quantification of fluorescence properties of lymphocytes in peripheral blood mononuclear cell suspensions using a latent class model.

van Putten WL, de Vries W, Reinders P, Levering W, van der Linden R, Tanke HJ, Bolhuis RL, Gratama JW.

Cytometry. 1993;14(1):86-96.

Supplemental Content

Loading ...
Support Center